Advanced Power Electronics Corp. (USA), a leading manufacturer of MOS power semiconductors for DC-DC power conversion applications, today announced new quad complementary N- and P-channel...
LifeMap Sciences, Inc. Announces Addition to Board of Directors and Provides Update on Product Portfolio DevelopmentOctober 19, 2012 9:00 am | by The Associated Press | News | Comments
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct 19, 2012--BioTime, Inc. (NYSE MKT: BTX) and its subsidiary, LifeMap Sciences, Inc., today announced the appointment of Louis E. Silverman to LifeMap Sciences’ board of directors. Mr. Silverman is an experienced health care executive with board level and...
FLAGSTAFF, Ariz.--(BUSINESS WIRE)--Oct 19, 2012--W. L. Gore & Associates (Gore) today reported the first patient enrolled in the GORE® Septal Occluder Clinical Study evaluating the safety and efficacy of the new GORE Septal Occluder in the treatment of percutaneous, trancatheter closure of...
A Cambridge biotech focused on neurodegenerative diseases reported positive data with its pre-clinical model for Parkinson’s disease (PD). With financial support from the Michael J. Fox Foundation announced in February, NeuroPhage Pharmaceuticals Inc. has developed NPT001, a drug candidate with the potential to disrupt and clear amyloid aggregates in the brain.
Health IT firm athenahealth Inc. (NASDAQ: ATHN) saw its stock sink almost 9 percent Friday, after revenues for the most recent quarter came in below expectations.
Millennium: The Takeda Oncology Company began a second Phase 3 trial on its drug candidate which is already being tested on blood cancer, this time to treat the most common form of amyloidosis, a group of diseases resulting from abnormal deposits of certain proteins.
Baxter shares tick up on Street-meeting 3rd-quarter results and an affirmed 2012 sales outlook. Baxter (NYSE:BAX) shares closed up a tad today after the healthcare company reported 3rd-quarter results in line with its guidance and affirmed its sales outlook for the rest of the year. News Well, 2012, MassDevice Earnings Roundup, Q3read more
A federal judge denies Coloplast's motion to dismiss a personal injury lawsuit filed over the Virtue ventral urethral elevation sling. Coloplast (CPH:COLO B) can't dodge a personal injury lawsuit filed in a Colorado federal court over its Virtue urethral sling, but the majority of the counts and moves for legal fees and punitive damages were stricken from the case. Legal News, News Well, Urologyread more
A Delaware state court rules that NuVasive can review documents covering current and former employees' contacts with Lanx, which NuVasive accuses of poaching its talent. NuVasive Inc. (NSDQ:NUVA) can review documents covering Lanx Inc.'s contacts with current and former NUVA employees it alleges were poached by Lanx. Legal News, News Well, Personnelread more
Minneapolis-based medical device titan Medtronic received Japanese regulatory approval for its Advisa DR MRI SureScan pacing systems, the first MR-Conditional pacemaker system in Japan. Medical device titan Medtronic (NYSE:MDT) landed Japanese regulatory approval for its Advisa MRI SureScan pacing system, which allows patients to have full-body scans without positioning limitations during the MRI scanner procedure. News Well, Cardiac Rhythm Management, Regulatory/Complianceread more
California Technology Assessment Forum Recommends Use Of Cell-Free DNA Technology As Advanced Prenatal Testing For Pregnant Women At High Risk For Fetal Chromosomal AnomaliesOctober 18, 2012 4:00 pm | by The Associated Press | News | Comments
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced that the California Technology Assessment Forum completed an independent evaluation of the cell-free fetal DNA technology used in the Sequenom Center...
I tried hard to find a topic other than the coming medical device excise tax to write about, however, either my brain didn’t have any more room to fit another topic or there’s just not that much else going on in the medical device industry (which is much less likely). I was also hesitant to write the column because, unlike with the web, there is a period of time that passes from the moment I complete the column until the time it is published and mailed where the content is out of my hands while outside forces can wreak havoc on the topic and the timing of its appearance.
Many medical device component manufacturers have to adjust their product formulations to meet growing market demand for protein-free alternatives to natural rubber and natural rubber latex (NR/NRL). As simple as this may sound, this change not only requires the use of unfamiliar raw materials, but also requires new processes and a certain amount of trial and error before manufacturers discover the best NR/NRL alternatives for their formulations. One thing they can agree upon is that not all NRL alternatives are created equally.
It’s not the journey, it’s the destination. In the case of interventional cardiovascular devices, both the journey and the destination are vital. These devices need to navigate the tortuous pathways of the vasculature in order to access and treat complex distal lesions. Getting there isn’t always easy.
When a manufacturer picks up a cardiovascular device, they literally hold someone’s life. There is no room for flaws in the quality of this product, or any other in the cardiovascular realm. These devices are shrinking, while becoming increasingly advanced—more intricate parts achieve more complex functions, within a surface area that leaves only enough space for perfection. So the case has never been greater for quality assurance. Conducting risk analysis through variation analysis software can satisfy it.